Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
6.18
-0.20 (-3.13%)
Mar 9, 2026, 1:42 PM EDT - Market open
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$396,333
Profits / Employee
-$2,685,526
Market Cap
542.82M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Rigel Pharmaceuticals | 164 |
| Alpha Tau Medical | 125 |
| Solid Biosciences | 100 |
| Ocugen | 95 |
| enGene Holdings | 82 |
| Larimar Therapeutics | 65 |
| Design Therapeutics | 55 |
VSTM News
- 4 days ago - Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 19 days ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 4 weeks ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 7 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC - Seeking Alpha
- 2 months ago - Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Business Wire